Last reviewed · How we verify
ATG
ATG (Antithymocyte Globulin) is a polyclonal antibody that depletes T lymphocytes by binding to T-cell antigens and triggering their destruction.
ATG (Antithymocyte Globulin) is a polyclonal antibody that depletes T lymphocytes by binding to T-cell antigens and triggering their destruction. Used for Prevention of acute organ rejection in renal transplant recipients, Treatment of acute rejection episodes in transplant patients, Aplastic anemia.
At a glance
| Generic name | ATG |
|---|---|
| Also known as | ATG Grafalon, Thymoglobulin, Anti-Human Thymocyte Globulin, antithymocyte globulin, Antithymocyte Globulin |
| Sponsor | ITB-Med LLC |
| Drug class | Polyclonal antithymocyte antibody |
| Target | T-cell surface antigens (CD2, CD3, CD4, CD8, and other T-cell markers) |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
ATG works by targeting and eliminating T cells, which are key drivers of immune-mediated rejection and autoimmune responses. It is produced by immunizing animals (typically rabbits or horses) against human thymus cells, generating a mixture of antibodies against various T-cell surface antigens. This T-cell depletion reduces the immune response in transplant rejection and certain autoimmune conditions.
Approved indications
- Prevention of acute organ rejection in renal transplant recipients
- Treatment of acute rejection episodes in renal transplant recipients
- Aplastic anemia (severe)
Common side effects
- Fever
- Chills
- Leukopenia
- Thrombocytopenia
- Infection
- Serum sickness
- Infusion reactions
Key clinical trials
- A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation (PHASE2, PHASE3)
- Upfront Autologous HSCT Versus Immunosuppression in Early Diffuse Cutaneous Systemic Sclerosis (PHASE4)
- Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations (PHASE2)
- Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients (PHASE2)
- Ruxolitinib-Decitabine Intensified Conditioning Regimen for AML: A Randomized Trial (PHASE4)
- Study on the Efficacy and Safety of the TmBU Conditioning Regimen in High-risk or Relapsed/Refractory Acute Leukemia (PHASE2)
- Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation (PHASE2)
- Study Comparing Reduced Versus Standard Dose Post-transplantation Cyclophosphamide in Combination With Post-engraftment Anti-thymoglobin as Graft Versus Host Disease Prophylaxis in Alternative Donor Peripheral Stem Cell Transplantation (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ATG CI brief — competitive landscape report
- ATG updates RSS · CI watch RSS
- ITB-Med LLC portfolio CI